Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 3Breast Neoplasms 3Lymphoma, Non-Hodgkin 2Leukemia 2Triple Negative Breast Neoplasms 1Teratoma 1Rhabdomyosarcoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, AIDS-Related 1Lymphoma 1Inflammatory Breast Neoplasms 1Infiltrating Bladder Urothelial Carcinoma 1Glioma 1Choriocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Embryonal 1Burkitt Lymphoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 26fludarabine 18Dexamethasone 17pembrolizumab 12Rituximab 11Etoposide 10venetoclax 9pomalidomide 9Gemcitabine 9fludarabine phosphate 7daratumumab 7Lenalidomide 7Bortezomib 7carfilzomib 6obinutuzumab 5glofitamab 5Vincristine 5Temozolomide 5Prednisone 5Nivolumab 5Immunotherapy, Adoptive 5Cisplatin 5Calcium Dobesilate 5selinexor 4cemiplimab 4Doxorubicin 4Cytarabine 4Carboplatin 4zanubrutinib 3ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × pegfilgrastim × 90 days × Clear all
NCT01840566 2026-05-28

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
17 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡